7T MRS in Parkinson's Disease

Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01237210

Enrollment

Registered

2010-11-09

Start date

2010-02-28

Completion date

2019-02-28

Last updated

2019-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's Disease, PD, magnetic resonance spectroscopy

Brief summary

This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan. 1. The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage. 2. There will be a relationship between neurochemical changes and disease severity.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

Parkinson's disease Group * Parkinson's disease (clinical diagnostic criteria) * Age 45-75 years inclusive * Able to safely undergo MRI scanning * Absence of diabetes and smoking * Capable of giving informed consent Healthy Control Group * Age 45-75 years inclusive * Able to safely undergo MRI scanning * Absence of diabetes and smoking * Capable of giving informed consent

Exclusion criteria

Parkinson's disease Group * Dementia (clinically determined by PI Dr. Tuite) * Diagnosis of atypical parkinsonism * Inability to safely undergo MRI scanning * Inability to give informed consent * Unstable medical conditions * Present smoker * Diabetic (on oral or injectable medications for diabetes) * Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan * Does not meet age criteria Healthy Control Group * Has a 1st degree relative with PD * Dementia (clinically determined by PI Dr. Tuite) * Inability to safely undergo MRI scanning * Inability to give informed consent * Unstable medical conditions * Present smoker * Diabetic (on oral or injectable medications for diabetes) * Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan * Does not meet age criteria

Design outcomes

Primary

Measure	Time frame	Description
Magnetic resonance spectroscopy (MRS)	Baseline	We will utilize optimized magnetic resonance spectroscopy (MRS) methodology to address theories of pathogenesis of Parkinson's disease (PD) by quantifying glutathione (GSH), lactate, glutamine and myo-inositol levels of the unilateral substantia nigra (SN) of healthy volunteers and patients with PD.

Countries

United States

Outcome results